AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Clinical Trials
35
25 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2005
Active, not recruiting
24
68.6%
Completed
4
11.4%
Not yet recruiting
1
2.9%
Recruiting
4
11.4%
Terminated
1
2.9%
Unknown
1
2.9%
No approval data available
No news articles found
